Leuprorelin not checked

LG Chem

FollowEvery change as it happens, and a Monday email
Next date
Phase 4 trial completes
Trials
8 active
10 in total · 9 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Central Precocious Puberty
Main trialPhase 4
“A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty”In the company’s words, NCT07710430 on ClinicalTrials.gov

Other drugs for Central Precocious Puberty

All 2 drugs for Central Precocious Puberty

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 30 Aug 2029 A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
Phase 3Authorised not given Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
Phase 3Ended not given The AGAINST-PLD; An investigator-driven, randomized, open label clinical trial assessing efficacy of leuprorelin to halt disease progression in PLD
Phase 3Authorised not given EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE)
Phase 3Authorised not given ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy
Phase 3Authorised not given GETUG 20 : Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence
Phase 4Authorised not given Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study
Phase 3Authorised not given Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial
Phase 2Ended not given EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate cancer: the ENHANCE prospective feasibility trial
Phase 3Authorised not given OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Leuprorelin

Following is part of Solo: you see every change to Leuprorelin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in